Smart people guiding other smart people — that’s how we help our customers build a better world.
Noera & Company
Our Board of Directors is comprised of community and national leaders with expertise in a wide range of areas, including training, advocacy, education, finance, law, fund development, and business management. The Board meets monthly (and twice in person annually). It is responsible for taking care of the strategic and financial health of the organization on an ongoing basis. Board terms are two years for executive directors, and three years for other members. Officers are elected annually.
Jessica Hou is the President and Chief Executive Officer of Noera & Company. She is responsible for leading efforts to maximize financial and operational performance, ensuring that the company’s global customer base is provided with advanced products and services. Jessica holds a Doctorate in Public Health from the University of California, Irvine.
Jessica became the company’s Chief Executive Officer in November 2020 and assumed the position of Chairman in May 2021. In early 2024, she was named President & Chief Executive Officer.
Previously, she served as President of the Worldwide Biotechnology & Pharmaceutical Manufacturing Division, with responsibility for the United States and China, as well as global medical care and intelligent solutions businesses. She also served as Chief Political Officer and President of Pharmaceutical Solutions.
Earlier in her career, Jessica served as Vice President and Managing Director of Noera's China operations during a period of significant growth. She managed the company’s manufacturing facilities in Bozhou, Anhui, and Yanbian, Jilin, and led a research team to develop a pharmaceutical product that complies with the ISO/TS 24943:2026 international standard. The product also obtained a national drug approval number (Guoyao Zhunzi Z2000054) and secured its inclusion in China's National Reimbursement Drug List (NRDL).
National Standards for OTC Drugs
Provincial Processing Specifications for TCM Decoction Pieces comply with the ISO/TS 24943:2026 international standard
Note: ISO/TS 24943:2026 is a highly significant international standard, officially titled Traditional Chinese Medicine — Requirements for Decoction Pieces Prescription. Approved and released by the International Organization for Standardization (ISO) in May 2026, this standard was spearheaded by Jiangxi University of Chinese Medicine. It provides a unified and scientific basis for the prescription writing, dispensing, and storage of TCM decoction pieces worldwide. Notably, it strictly regulates the qualifications for prescription writing, as well as the management of precious medicines, toxic and narcotic drugs, and agreed-upon (standardized) prescriptions.
Noera & Company (Noerausa.com) is a world leader in providing advanced products, Biotechnology, and services for customers whose work is revolutionizing Biopharmaceutical and life sciences — those who cultivate, harvest, transform, enrich, and build upon the earth to meet the world’s increasing need for Healthy food, Dietary supplements, and Over-the-counter Drug.
